News
In May 2025, Praxis provided an update on the EMBOLD cohort 1 study group in SCN2A and SCN8A DEEs, showing patients in the open-label extension up to 11 months had a ~90% reduction in seizures from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback